434 related articles for article (PubMed ID: 26215403)
21. Pronounced transcriptional regulation of apoptotic and TNF-NF-kappa-B signaling genes during the course of thymoquinone mediated apoptosis in HeLa cells.
Sakalar C; Yuruk M; Kaya T; Aytekin M; Kuk S; Canatan H
Mol Cell Biochem; 2013 Nov; 383(1-2):243-51. PubMed ID: 23943306
[TBL] [Abstract][Full Text] [Related]
22. Thymoquinone suppression of the human hepatocellular carcinoma cell growth involves inhibition of IL-8 expression, elevated levels of TRAIL receptors, oxidative stress and apoptosis.
Ashour AE; Abd-Allah AR; Korashy HM; Attia SM; Alzahrani AZ; Saquib Q; Bakheet SA; Abdel-Hamied HE; Jamal S; Rishi AK
Mol Cell Biochem; 2014 Apr; 389(1-2):85-98. PubMed ID: 24399465
[TBL] [Abstract][Full Text] [Related]
23. Implication of thymoquinone as a remedy for polycystic ovary in rat.
Arif M; Thakur SC; Datta K
Pharm Biol; 2016; 54(4):674-85. PubMed ID: 26510692
[TBL] [Abstract][Full Text] [Related]
24. FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-κB pathway.
Liu YK; Jia YJ; Liu SH; Ma J
Cancer Chemother Pharmacol; 2021 Mar; 87(3):405-414. PubMed ID: 33392640
[TBL] [Abstract][Full Text] [Related]
25. Thymoquinone induces G2/M arrest, inactivates PI3K/Akt and nuclear factor-κB pathways in human cholangiocarcinomas both in vitro and in vivo.
Xu D; Ma Y; Zhao B; Li S; Zhang Y; Pan S; Wu Y; Wang J; Wang D; Pan H; Liu L; Jiang H
Oncol Rep; 2014 May; 31(5):2063-70. PubMed ID: 24603952
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.
Liu J; Viswanadhapalli S; Garcia L; Zhou M; Nair BC; Kost E; Rao Tekmal R; Li R; Rao MK; Curiel T; Vadlamudi RK; Sareddy GR
Oncotarget; 2017 Jul; 8(30):50002-50014. PubMed ID: 28654894
[TBL] [Abstract][Full Text] [Related]
27. Thymoquinone synergizes with arsenic and interferon alpha to target human T-cell leukemia/lymphoma.
Houssein M; Fatfat M; Habli Z; Ghazal N; Moodad S; Khalife H; Khalil M; Gali-Muhtasib H
Life Sci; 2020 Jun; 251():117639. PubMed ID: 32272181
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-κB-TNFα-PIK3CA loop.
Thakur B; Ray P
J Exp Clin Cancer Res; 2017 Nov; 36(1):164. PubMed ID: 29169370
[TBL] [Abstract][Full Text] [Related]
29. Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer.
Glass EB; Hoover AA; Bullock KK; Madden MZ; Reinfeld BI; Harris W; Parker D; Hufnagel DH; Crispens MA; Khabele D; Rathmell WK; Rathmell JC; Wilson AJ; Giorgio TD; Yull FE
BMC Cancer; 2022 May; 22(1):497. PubMed ID: 35513776
[TBL] [Abstract][Full Text] [Related]
30. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
Shen W; Liang B; Yin J; Li X; Cheng J
Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
[TBL] [Abstract][Full Text] [Related]
31. Dual targeting of GSK3B and HDACs reduces tumor growth and improves survival in an ovarian cancer mouse model.
Taylan E; Zayou F; Murali R; Karlan BY; Pandol SJ; Edderkaoui M; Orsulic S
Gynecol Oncol; 2020 Oct; 159(1):277-284. PubMed ID: 32698955
[TBL] [Abstract][Full Text] [Related]
32. Molecular targeting of Akt by thymoquinone promotes G(1) arrest through translation inhibition of cyclin D1 and induces apoptosis in breast cancer cells.
Rajput S; Kumar BN; Dey KK; Pal I; Parekh A; Mandal M
Life Sci; 2013 Nov; 93(21):783-90. PubMed ID: 24044882
[TBL] [Abstract][Full Text] [Related]
33. Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer.
Wilson AJ; Gupta VG; Liu Q; Yull F; Crispens MA; Khabele D
Neoplasia; 2022 Feb; 24(2):63-75. PubMed ID: 34933276
[TBL] [Abstract][Full Text] [Related]
34. Thymoquinone Augments Cisplatin-Induced Apoptosis on Esophageal Carcinoma Through Mitigating the Activation of JAK2/STAT3 Pathway.
Hu X; Ma J; Vikash V; Li J; Wu D; Liu Y; Zhang J; Dong W
Dig Dis Sci; 2018 Jan; 63(1):126-134. PubMed ID: 29197940
[TBL] [Abstract][Full Text] [Related]
35. Wounding promotes ovarian cancer progression and decreases efficacy of cisplatin in a syngeneic mouse model.
Lee Y; Kollara A; May T; Brown TJ
J Ovarian Res; 2018 Jul; 11(1):56. PubMed ID: 29973223
[TBL] [Abstract][Full Text] [Related]
36. Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer.
Hijaz M; Das S; Mert I; Gupta A; Al-Wahab Z; Tebbe C; Dar S; Chhina J; Giri S; Munkarah A; Seal S; Rattan R
BMC Cancer; 2016 Mar; 16():220. PubMed ID: 26979107
[TBL] [Abstract][Full Text] [Related]
37. CKD712, a synthetic isoquinoline alkaloid, enhances the anti-cancer effects of paclitaxel in MDA-MB-231 cells through regulation of PTEN.
Kim YM; Tsoyi K; Jang HJ; Park EJ; Park SW; Kim HJ; Hwa JS; Chang KC
Life Sci; 2014 Sep; 112(1-2):49-58. PubMed ID: 25058922
[TBL] [Abstract][Full Text] [Related]
38. Thymoquinone enhances the anticancer activity of doxorubicin against adult T-cell leukemia in vitro and in vivo through ROS-dependent mechanisms.
Fatfat M; Fakhoury I; Habli Z; Mismar R; Gali-Muhtasib H
Life Sci; 2019 Sep; 232():116628. PubMed ID: 31278946
[TBL] [Abstract][Full Text] [Related]
39. TNF-α-mediated NF-κB survival signaling impairment by cisplatin enhances JNK activation allowing synergistic apoptosis of renal proximal tubular cells.
Benedetti G; Fredriksson L; Herpers B; Meerman J; van de Water B; de Graauw M
Biochem Pharmacol; 2013 Jan; 85(2):274-86. PubMed ID: 23103562
[TBL] [Abstract][Full Text] [Related]
40. [Role of NF-κB in the anti-tumor effect of thymoquinone on bladder cancer].
Mu HQ; Yang S; Wang YJ; Chen YH
Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(6):392-6. PubMed ID: 22490899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
